Data / Research funding / North Carolina / Eydis Bio, Inc.
Eydis Bio, Inc.: 6 NIH awards ($6.4M), fiscal years 2021 to 2026
Eydis Bio, Inc. in Durham, NC is funded under 6 NIH awards ($6.4M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- MWWCM7JMBCF1
- State
- North Carolina
Awards
6 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Novel compounds for the treatment of systemic sclerosis-associated interstitial lung disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $2,600,290 | July 15, 2024 | June 30, 2027 | SCARNEO, SCOTT | reporter.nih.gov |
| Preclinical Development of the TAK1 Inhibitor HS-276 for the Treatment of Rheumatoid Arthritis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $1,709,883 | September 22, 2021 | August 31, 2024 | SCARNEO, SCOTT | reporter.nih.gov |
| Acute Inhibition of TAK1 as a Means to Control COVID-19 Pulmonary Hyperinflammation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $593,995 | August 1, 2021 | May 31, 2024 | SCARNEO, SCOTT | reporter.nih.gov |
| Development of orally bioavailable and blood-brain barrier penetrant, small molecule TAK1 inhibitors as a novel treatment for Alzheimer's Disease | NIH | National Institute on Aging | 2024 | $506,267 | September 15, 2024 | May 31, 2026 | SCARNEO, SCOTT | reporter.nih.gov |
| Discovery and Development of Oral Small-molecule Direct-acting Antivirals | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $499,825 | September 29, 2025 | September 29, 2026 | SCARNEO, SCOTT | reporter.nih.gov |
| Evaluating the Blood-Brain Barrier Bioavailability and in vivo Efficacy Potential of a Novel TAK1 Inhibitor Targeting Chronic Pain | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $480,955 | September 8, 2021 | August 31, 2023 | SCARNEO, SCOTT | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 2 | $1,917,483 | 0 | $0 |
| 2024 | 2 | $1,688,899 | 0 | $0 |
| 2022 | 2 | $1,197,804 | 0 | $0 |
| 2021 | 3 | $1,587,029 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Topics of its NIH awards
- Arthritis
- Autoimmune Disease
- Infectious Diseases
- Orphan Drug
- Rare Diseases
- Brain Disorders
- Neurodegenerative
- Neurosciences
- Emerging Infectious Diseases
- Lung
- Rheumatoid Arthritis
- Women's Health
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.